Anebulo Pharmaceuticals, Inc. (ANEB) News
Filter ANEB News Items
ANEB News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest ANEB News From Around the Web
Below are the latest news stories about ANEBULO PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ANEB as an investment opportunity.
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent UpdatesAUSTIN, Texas, November 14, 2023--Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent Updates |
Here's Why We're Watching Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn SituationEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
Are Medical Stocks Lagging Anebulo Pharmaceuticals (ANEB) This Year?Here is how Anebulo Pharmaceuticals, Inc. (ANEB) and Conmed (CNMD) have performed compared to their sector so far this year. |
Anebulo Pharmaceuticals Announces New CEOAUSTIN, Texas, October 06, 2023--Anebulo Pharmaceuticals Announces New CEO |
Anebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of DirectorsAUSTIN, Texas, October 06, 2023--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) ("Anebulo"), today announced the appointment of Bimal Shah to its Board of Directors. Mr. Shah will serve as a member of the board’s audit and compensation committees. |
Are Medical Stocks Lagging Exact Sciences (EXAS) This Year?Here is how Exact Sciences (EXAS) and Anebulo Pharmaceuticals, Inc. (ANEB) have performed compared to their sector so far this year. |
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent UpdatesAUSTIN, Texas, September 20, 2023--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse (the "Company" or "Anebulo"), today announced financial results for the three and twelve months ended June 30, 2023, and recent updates. |
Anebulo Pharmaceuticals to Present at Upcoming Investor and Scientific ConferencesAUSTIN, Texas, August 30, 2023--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse (the "Company" or "Anebulo"), today announced that it will be giving an investor presentation at the H.C. Wainwright 25th Annual Global Investment Conference, from September 11 to September 13. In addition, the Company announced the acceptance of three presentations at |
Anebulo (ANEB) Gains on Positive FDA Response for ANEB-001Anebulo (ANEB) gains on positive FDA response for the phase III development of its lead candidate ANEB-001 for treating patients with acute cannabinoid intoxication. |
Anebulo Receives Positive Feedback from FDA on Path to Advance Phase 3 Clinical Development of ANEB-001 and Completes Dosing of Phase 2 ExtensionAUSTIN, Texas, August 21, 2023--Anebulo Receives Positive Feedback from FDA on Path to Advance Phase 3 Clinical Development of ANEB-001 and Completes Dosing of Phase 2 Extension |